Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 20/20 | 0.65 |
| ▸ | PPARD | Q03181 | 7/20 | 0.65 |
| ▸ | PPARG | P37231 | 9/20 | 0.58 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607956 | 1.00 | PPARA (0.65) | PPARAPPARDPPARGPSEN1PSEN2 | |
| SCHEMBL5607822 | 0.91 | PPARA (0.56) | PPARAPPARDPPARG | |
| SCHEMBL5080127 | 0.91 | PPARA (0.56) | PPARAPPARDPPARG | |
| SCHEMBL5608111 | 0.85 | HPGD (0.71) | PPARAPPARDPPARG | |
| SCHEMBL5608115 | 0.85 | HPGD (0.71) | PPARAPPARDPPARG | |
| SCHEMBL5607245 | 0.82 | PPARG (0.72) | PPARAPPARG | |
| SCHEMBL5607252 | 0.82 | PPARG (0.72) | PPARAPPARG | |
| SCHEMBL5607786 | 0.81 | NR1H4 (0.71) | — | |
| SCHEMBL5607801 | 0.81 | NR1H4 (0.71) | — | |
| SCHEMBL5607223 | 0.81 | SMN1; SMN2 (0.58) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | PPARA 448/4885PPARD 256/4885PPARG 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.